ICV

International Cruise Victims Association (ICV) calls for the Cruise Industry to Cease Operations into or out of United States Ports to Aid in the Containment of the COVID-19 Virus

Retrieved on: 
Thursday, March 12, 2020

ICV has been a bold watchdog over the cruise industry, testifying in congressional hearings, promoting and successfully seeing historic legislation passed.

Key Points: 
  • ICV has been a bold watchdog over the cruise industry, testifying in congressional hearings, promoting and successfully seeing historic legislation passed.
  • With the spread of the COVID-19 virus, we cannot sit idly by and watch the cruise industry put their passengers, crew, and the global population at risk.
  • We know from years of data collection that the cruise industry has historically been deficient in preventing or controlling viral outbreaks on their ships.
  • Therefore, ICV implores the cruise industry to earnestly now put passengers and public safety first.

Leading Utility Alectra Inc. Invests $5M in Grid4C via Its Professional Services Company Util-Assist Inc. to Scale Its #1 Ranked AI-Powered Energy Analytics

Retrieved on: 
Tuesday, January 28, 2020

The models automatically disaggregate and predict usage for appliances behind the meter and are aggregated to deliver predictions for grid assets.

Key Points: 
  • The models automatically disaggregate and predict usage for appliances behind the meter and are aggregated to deliver predictions for grid assets.
  • The companys solutions improve operational planning, reduce peak demand, increase energy savings, deliver new revenue streams, and increase customer engagement.
  • Util-Assist is a wholly owned subsidiary of Alectra Energy Solutions Inc. which is a branch of the Alectra Utilities family of companies.
  • The Alectra family of companies includes Alectra Inc., Alectra Utilities Corporation and Alectra Energy Solutions Inc.

International Cruise Victims Association Exposes Fatal Boat Fire Complicity

Retrieved on: 
Monday, September 16, 2019

The International Cruise Victims Association (ICV), a network of families and survivors, is all too familiar with the consequences when boat operators are not held accountable for safety.

Key Points: 
  • The International Cruise Victims Association (ICV), a network of families and survivors, is all too familiar with the consequences when boat operators are not held accountable for safety.
  • The fatal fire on the Conception dive boat was devastating.
  • The quick legal maneuvers taken by the boat representatives to deflect responsibility are deplorable.
  • The cruise industry spends millions of dollars lobbying Congress to defend these outdated laws despite the mounting loss of life.

The International Cruise Victims Association is Pleased to Announce That Senator Deb Fischer Introduces Major Legislation to End DOHSA

Retrieved on: 
Thursday, April 11, 2019

This is the ICV organizations response to the announcement made yesterday by Senator Deb Fischer (R-Neb.)

Key Points: 
  • This is the ICV organizations response to the announcement made yesterday by Senator Deb Fischer (R-Neb.)
  • These passengers, Senator Fischer says, include children, students, and retirees which account for a significant portion of the 12 million Americans who cruise each year.
  • We are grateful to Senator Fischer for introducing Hammers' Law to safeguard the millions of Americans who cruise each year."
  • International Cruise Victims joins with Senator Fischer and the Hammer family in calling for this inequity to be exposed and eliminated.

Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug

Retrieved on: 
Thursday, April 4, 2019

and GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280) today announced an exclusive licensing agreement in Japan to commercialize Hunterase (Idursulfase-beta) ICV, a human recombinant iduronate-2-sulfatase (IDS) used in enzyme replacement therapy for the treatment of Hunter syndrome.

Key Points: 
  • and GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280) today announced an exclusive licensing agreement in Japan to commercialize Hunterase (Idursulfase-beta) ICV, a human recombinant iduronate-2-sulfatase (IDS) used in enzyme replacement therapy for the treatment of Hunter syndrome.
  • Used as one of the methods for Hunter syndrome treatment, intravenous injection does not penetrate the blood brain barrier in clinically adequate amounts.
  • Hunterase (Idursulfase-beta) ICV developed by GC Pharma is delivered directly to cerebral ventricles by intracerebroventricular (ICV) administration, in order to reach the cells of the brain and central nervous system.
  • "We are delighted to further enhance the value of Hunterase through this partnership," said Eun Chul Huh, Ph.D., President at GC Pharma.

ICV Partners Announces Promotion of John Wallace to Managing Director and Appointment of Everett Hill as Managing Director

Retrieved on: 
Tuesday, January 8, 2019

NEW YORK, Jan. 8, 2019 /PRNewswire/ --ICV Partners (ICV), a leading investment firm focused on lower middle market companies, announced today the promotion of John Wallace to Managing Director and the appointment of Everett Hill as Managing Director.

Key Points: 
  • NEW YORK, Jan. 8, 2019 /PRNewswire/ --ICV Partners (ICV), a leading investment firm focused on lower middle market companies, announced today the promotion of John Wallace to Managing Director and the appointment of Everett Hill as Managing Director.
  • He further strengthens our Atlanta office and we look forward to working with Everett in this new full-time capacity."
  • Prior to joining ICV, Mr. Wallace was an independent consultant with Chastain Advisors, a firm he founded.
  • Founded in 1998, ICV Partners is a leading private investment firm that supports management leaders of strong middle market companies.